About Coronary Artery Disease Therapeutics Coronary artery disease (CAD) is the most common type of heart disease and is one of the leading causes of death globally. It can lead to complications including myocardial infarction, stable angina, unstable angina, and sudden cardiac death. CAD is the narrowing of the coronary arteries that prevents the supply of an adequate amount of blood supply to the heart. It happens when a coronary artery gets hardened or narrowed due to various reasons such as the build-up of cholesterol or other materials known as plaque on the inner wall of the artery. This build-up is known as atherosclerosis. With passing time, a lesser amount of blood flows through the arteries. As a result heart muscle fails to get the required amount of blood or oxygen. Technavio’s analysts forecast the global coronary artery disease therapeutics market to grow at a CAGR of 5.17% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global coronary artery disease therapeutics... Research Beam Model: Research Beam Product ID: 2669993 3500 USD New
Global Coronary Artery Disease Therapeutics Market 2017-2021
 
 

Global Coronary Artery Disease Therapeutics Market 2017-2021

  • Category : Healthcare
  • Published On : October   2017
  • Pages : 100
  • Publisher : Technavio
 
 
 
About Coronary Artery Disease Therapeutics

Coronary artery disease (CAD) is the most common type of heart disease and is one of the leading causes of death globally. It can lead to complications including myocardial infarction, stable angina, unstable angina, and sudden cardiac death. CAD is the narrowing of the coronary arteries that prevents the supply of an adequate amount of blood supply to the heart. It happens when a coronary artery gets hardened or narrowed due to various reasons such as the build-up of cholesterol or other materials known as plaque on the inner wall of the artery. This build-up is known as atherosclerosis. With passing time, a lesser amount of blood flows through the arteries. As a result heart muscle fails to get the required amount of blood or oxygen.

Technavio’s analysts forecast the global coronary artery disease therapeutics market to grow at a CAGR of 5.17% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global coronary artery disease therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Coronary Artery Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• AstraZeneca
• Gilead
• Novartis
• Pfizer
Other prominent vendors
• Bayer,
• Bristol-Myers Squibb,
• GlaxoSmithKline,
• Merck,
• Mylan,
• Teva Pharmaceutical Industries
Market driver
• Growing geriatric population
• For a full, detailed list, view our report

Market challenge
• Highly genericized market
• For a full, detailed list, view our report

Market trend
• Growing strategic alliances
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
• Disease definition
• Risk factors for CAD
• Diagnosis
• Treatment options
PART 05: MARKET LANDSCAPE
• Market overview
• Five forces analysis
PART 06: PIPELINE LANDSCAPE
PART 07: MARKET SEGMENTATION BY DRUG CLASS
• Comparison by drug class
• Beta-blockers
• Calcium channel blockers
• Nitrates
• ACE inhibitors
• Others
• Market opportunity
PART 08: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• CAD therapeutics in Americas
• CAD therapeutics in EMEA
• CAD therapeutics in APAC
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Growing strategic alliances
• Investment inclination toward developing countries
PART 12: VENDOR LANDSCAPE
• Competitive landscape
PART 13: VENDOR ANALYSIS
• Vendor overview
PART 14: KEY VENDORS
• AstraZeneca
• Gilead
• Novartis
• Pfizer
PART 15: APPENDIX
• List of abbreviations

Exhibit 01: Symptoms of CAD
Exhibit 02: Types of angina
Exhibit 03: Few selected risk factors
Exhibit 04: Diagnosis and treatment of CAD
Exhibit 05: Global CAD therapeutics market snapshot
Exhibit 06: Opportunity analysis in global CAD therapeutics market
Exhibit 07: Global CAD therapeutics market 2016-2021 ($ millions)
Exhibit 08: Five forces analysis
Exhibit 09: Pipeline molecules by key vendors
Exhibit 10: Key clinical trials
Exhibit 11: Global CAD therapeutics market segmentation by drug class 2016-2021
Exhibit 12: Comparison by drug class
Exhibit 13: Common beta-blockers used in cardiovascular diseases
Exhibit 14: Adverse effects of beta-blockers
Exhibit 15: Beta-blockers for CAD treatment – Market size and forecast 2016-2021 ($ millions)
Exhibit 16: Beta-blockers for CAD treatment – Year-over-year (YoY) growth 2017-2021
Exhibit 17: Frequent use of beta-blockers in some of the common cardiovascular conditions
Exhibit 18: Common calcium channel blockers used for CAD treatment
Exhibit 19: Antianginal effects of calcium channel blockers
Exhibit 20: Adverse effects of calcium channel blockers
Exhibit 21: Calcium channel blockers for CAD treatment – Market size and forecast 2016-2021 ($ millions)
Exhibit 22: Calcium channel blockers for CAD treatment – YoY growth 2017-2021
Exhibit 23: Dosage forms of nitrates for CAD treatment
Exhibit 24: Nitrates for CAD treatment – Market size and forecast 2016-2021 ($ millions)
Exhibit 25: Nitrates for CAD treatment – YoY growth 2017-2021
Exhibit 26: Adverse effects of ACE inhibitors
Exhibit 27: ACE inhibitor for CAD treatment – Market size and forecast 2016-2021 ($ millions)
Exhibit 28: ACE inhibitors for CAD – YoY growth 2017-2021
Exhibit 29: Other drug classes used in CAD treatment
Exhibit 30: Overview of major antiplatelet agents in CAD treatment
Exhibit 31: Overview of major anti-ischemic agent in CAD treatment
Exhibit 32: Others for CAD treatment – Market size and forecast 2016-2021 ($ millions)
Exhibit 33: Others for CAD treatment – YoY growth 2017-2021
Exhibit 34: Geographical segmentation of global CAD therapeutics market 2016-2021
Exhibit 35: Regional comparison
Exhibit 36: CAD therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 37: CAD therapeutics market YoY growth in Americas 2017-2021
Exhibit 38: CAD therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 39: CAD therapeutics market YoY growth in EMEA 2017-2021
Exhibit 40: CAD therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 41: Top Asian countries in terms of population with diabetes
Exhibit 42: CAD therapeutics market YoY growth in APAC 2017-2021
Exhibit 43: Key leading countries
Exhibit 44: World population by age group: 2015-2050 (millions)
Exhibit 45: Percentage of population aged 60 years and above by region 2015 and 2050
Exhibit 46: Major complications of diabetes
Exhibit 47: Global obesity facts 2014
Exhibit 48: Side effects of the drugs used in angina pectoris treatment and management
Exhibit 49: Demographic and economic snapshot of India and China
Exhibit 50: Competitive structure analysis of global CAD therapeutics market
Exhibit 51: AstraZeneca: Key highlights
Exhibit 52: AstraZeneca: Strength assessment
Exhibit 53: AstraZeneca: Strategy assessment
Exhibit 54: AstraZeneca: Opportunity assessment
Exhibit 55: Gilead: Key highlights
Exhibit 56: Gilead: Strength assessment
Exhibit 57: Gilead: Strategy assessment
Exhibit 58: Gilead: Opportunity assessment
Exhibit 59: Novartis: Key highlights
Exhibit 60: Novartis: Strength assessment
Exhibit 61: Novartis: Strategy assessment
Exhibit 62: Novartis: Opportunity assessment
Exhibit 63: Pfizer: Key highlights
Exhibit 64: Pfizer: Strength assessment
Exhibit 65: Pfizer: Strategy assessment
Exhibit 66: Pfizer: Opportunity assessment

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT